Generic formulation of Cyclosporine A, Equoral®, in de novo kidney transplant recipients: five-year follow-up.
Equoral(®) is a generic formulation of Cyclosporine A (CsA), which is significantly cheaper than the original medicine. Our center participated in the clinical trial designed to evaluate the efficacy and safety of Equoral(®) in kidney transplant recipients in the first 9 months after a transplant procedure. The aim of our paper is to present the 5-year follow-up of patients who participated in the study and were monitored in our center. We performed intention-to-treat retrospective analysis of 20 de novo kidney transplant recipients who received Equoral®-based immunosuppressive regimen and were monitored in our department for 5 years after transplantation. The 5-year patient and graft survival was 90%, and the frequency of acute rejection was 15%. In 80% of patients, the initial immunosuppressive regimen had to be changed. In our group of kidney transplant recipients, immunosuppression based on generic formulation of CsA had excellent 5-year patient and graft survival and effectively prevented acute rejection episodes. However, most patients needed modification of the initially administered immunosuppressive regimen.